Investment Analysts’ Recent Ratings Updates for Protagonist Therapeutics (PTGX)

Protagonist Therapeutics (NASDAQ: PTGX) has recently received a number of price target changes and ratings updates:

• 3/3/2025 – Protagonist Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
• 2/24/2025 – Protagonist Therapeutics had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $43.00 to $38.00. They now have a “neutral” rating on the stock.
• 2/24/2025 – Protagonist Therapeutics had its price target raised by analysts at HC Wainwright from $50.00 to $54.00. They now have a “buy” rating on the stock.
• 2/21/2025 – Protagonist Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $58.00 price target on the stock.
• 2/7/2025 – Protagonist Therapeutics had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $58.00 price target on the stock.
• 2/7/2025 – Protagonist Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
• 2/4/2025 – Protagonist Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. from $51.00 to $53.00. They now have an “overweight” rating on the stock.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ PTGX traded up $0.91 during midday trading on Monday, reaching $38.50. 2,393,485 shares of the company’s stock were exchanged, compared to its average volume of 669,945. The stock has a market capitalization of $2.36 billion, a PE ratio of 14.47 and a beta of 2.22. Protagonist Therapeutics, Inc. has a 52-week low of $24.22 and a 52-week high of $48.89. The business’s fifty day moving average price is $37.94 and its two-hundred day moving average price is $41.82.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $2.07. The company had revenue of $170.64 million for the quarter, compared to analyst estimates of $56.65 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. Analysts predict that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total value of $204,606.62. Following the completion of the sale, the chief executive officer now directly owns 540,260 shares in the company, valued at approximately $20,627,126.80. The trade was a 0.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Protagonist Therapeutics

A number of hedge funds have recently added to or reduced their stakes in PTGX. Bank of Montreal Can lifted its position in shares of Protagonist Therapeutics by 4.5% in the 4th quarter. Bank of Montreal Can now owns 6,250 shares of the company’s stock worth $241,000 after buying an additional 270 shares during the last quarter. Maryland State Retirement & Pension System lifted its holdings in Protagonist Therapeutics by 1.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company’s stock worth $779,000 after acquiring an additional 278 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in Protagonist Therapeutics by 10.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock worth $121,000 after acquiring an additional 295 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in Protagonist Therapeutics by 1.1% in the fourth quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company’s stock valued at $1,112,000 after acquiring an additional 300 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Protagonist Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company’s stock valued at $95,000 after purchasing an additional 379 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.